Gsk Plc (GSK.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Income taxes - deferred | 580,000 | 953,000 | 754,000 | 1,356,000 | 877,000 |
| Accounts receivable | -383,000 | -192,000 | -411,000 | -213,000 | 193,000 |
| Other Working Capital | 2,427,000 | 294,000 | 3,423,000 | 1,689,000 | 3,987,000 |
| Other Operating Activity | 5,817,000 | 6,965,000 | 4,655,000 | 4,086,000 | 1,440,000 |
| Operating Cash Flow | $8,441,000 | $8,020,000 | $8,421,000 | $6,918,000 | $6,497,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,158,000 | -1,170,000 | -1,176,000 | -1,264,000 | -1,445,000 |
| Net Acquisitions | 3,008,000 | -3,780,000 | -292,000 | 356,000 | 592,000 |
| Sale Of Investment | N/A | 1,000 | 0 | 4,000 | N/A |
| Purchase Sale Intangibles | 242,000 | -494,000 | -196,000 | -609,000 | -526,000 |
| Other Investing Activity | 1,324,000 | 493,000 | 367,000 | 118,000 | 393,000 |
| Investing Cash Flow | $2,161,000 | $-5,354,000 | $-1,553,000 | $-1,443,000 | $-1,269,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -7,305,000 | -1,065,000 | -1,986,000 | -3,200,000 | 148,000 |
| Debt Issued | 3,298,000 | 4,794,000 | 10,138,000 | 2,233,000 | 0 |
| Common Stock Issued | 29,000 | 51,000 | 74,000 | 56,000 | 89,000 |
| Common Stock Repurchased | N/A | 0 | 0 | -65,000 | -74,000 |
| Dividend Paid | -3,977,000 | -3,953,000 | -3,927,000 | -3,906,000 | -4,850,000 |
| Other Financing Activity | -2,177,000 | -1,667,000 | -10,688,000 | -1,498,000 | -1,705,000 |
| Financing Cash Flow | $-10,132,000 | $-1,840,000 | $-6,389,000 | $-6,380,000 | $-6,392,000 |
| Exchange Rate Effect | -39,000 | -82,000 | 8,000 | -100,000 | 283,000 |
| Beginning Cash Position | 4,831,000 | 4,087,000 | 3,600,000 | 4,605,000 | 5,486,000 |
| End Cash Position | 5,262,000 | 4,831,000 | 4,087,000 | 3,600,000 | 4,605,000 |
| Net Cash Flow | $470,000 | $826,000 | $479,000 | $-905,000 | $-1,164,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 8,441,000 | 8,020,000 | 8,421,000 | 6,918,000 | 6,497,000 |
| Capital Expenditure | -2,239,000 | -2,163,000 | -1,796,000 | -2,202,000 | -2,352,000 |
| Free Cash Flow | 6,202,000 | 5,857,000 | 6,625,000 | 4,716,000 | 4,145,000 |